New diabetes pill taken twice a month shows promise in Real-World study

NCT ID NCT07198932

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 27 times

Summary

This study looks at two diabetes medications, cofrogliptin and linagliptin, when added to insulin therapy in Chinese adults with type 2 diabetes. The goal is to see which one works better at controlling blood sugar and is safer. About 594 participants will take either cofrogliptin twice a month or linagliptin once a day, and researchers will track changes in blood sugar levels over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Affiliated Hospital of Hebei University

    Baoding, China

  • Beijing Luhe Hospital Affiliated to Capital Medical University

    Beijing, China

  • Qingpu Branch of Zhongshan Hospital Affiliated to Fudan University

    Shanghai, China

  • Shanghai Changzheng Hospital

    Shanghai, China

  • Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University

    Hangzhou, Zhejiang, China

  • Xi'an International Medical Center Hospital

    Xi'an, China

  • the First Medical Center of Chinese PLA General Hospital

    Beijing, China

Conditions

Explore the condition pages connected to this study.